These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 23704553)

  • 1. Comment on "ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models".
    Price AR; Xu G; Siemienski ZB; Smithson LA; Borchelt DR; Golde TE; Felsenstein KM
    Science; 2013 May; 340(6135):924-d. PubMed ID: 23704553
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comment on "ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models".
    Veeraraghavalu K; Zhang C; Miller S; Hefendehl JK; Rajapaksha TW; Ulrich J; Jucker M; Holtzman DM; Tanzi RE; Vassar R; Sisodia SS
    Science; 2013 May; 340(6135):924-f. PubMed ID: 23704555
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comment on "ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models".
    Tesseur I; Lo AC; Roberfroid A; Dietvorst S; Van Broeck B; Borgers M; Gijsen H; Moechars D; Mercken M; Kemp J; D'Hooge R; De Strooper B
    Science; 2013 May; 340(6135):924-e. PubMed ID: 23704554
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comment on "ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models".
    Fitz NF; Cronican AA; Lefterov I; Koldamova R
    Science; 2013 May; 340(6135):924-c. PubMed ID: 23704552
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Response to comments on "ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models".
    Landreth GE; Cramer PE; Lakner MM; Cirrito JR; Wesson DW; Brunden KR; Wilson DA
    Science; 2013 May; 340(6135):924-g. PubMed ID: 23704556
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models.
    Cramer PE; Cirrito JR; Wesson DW; Lee CY; Karlo JC; Zinn AE; Casali BT; Restivo JL; Goebel WD; James MJ; Brunden KR; Wilson DA; Landreth GE
    Science; 2012 Mar; 335(6075):1503-6. PubMed ID: 22323736
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Medicine. Old drug, new hope for Alzheimer's disease.
    Strittmatter WJ
    Science; 2012 Mar; 335(6075):1447-8. PubMed ID: 22442467
    [No Abstract]   [Full Text] [Related]  

  • 8. Early Treatment Critical: Bexarotene Reduces Amyloid-Beta Burden In Silico.
    Rosenthal J; Belfort G; Isaacson D
    PLoS One; 2016; 11(4):e0153150. PubMed ID: 27073866
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical success against Alzheimer's disease with an old drug.
    LaFerla FM
    N Engl J Med; 2012 Aug; 367(6):570-2. PubMed ID: 22873540
    [No Abstract]   [Full Text] [Related]  

  • 10. Clearing Amyloid-β through PPARγ/ApoE Activation by Genistein is a Treatment of Experimental Alzheimer's Disease.
    Bonet-Costa V; Herranz-Pérez V; Blanco-Gandía M; Mas-Bargues C; Inglés M; Garcia-Tarraga P; Rodriguez-Arias M; Miñarro J; Borras C; Garcia-Verdugo JM; Viña J
    J Alzheimers Dis; 2016; 51(3):701-11. PubMed ID: 26890773
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bexarotene Promotes Cholesterol Efflux and Restricts Apical-to-Basolateral Transport of Amyloid-β Peptides in an In Vitro Model of the Human Blood-Brain Barrier.
    Kuntz M; Candela P; Saint-Pol J; Lamartinière Y; Boucau MC; Sevin E; Fenart L; Gosselet F
    J Alzheimers Dis; 2015; 48(3):849-62. PubMed ID: 26402114
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Double-blind, placebo-controlled, proof-of-concept trial of bexarotene Xin moderate Alzheimer's disease.
    Cummings JL; Zhong K; Kinney JW; Heaney C; Moll-Tudla J; Joshi A; Pontecorvo M; Devous M; Tang A; Bena J
    Alzheimers Res Ther; 2016 Jan; 8():4. PubMed ID: 26822146
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Possible Molecular Interactions of Bexarotene - A Retinoid Drug and Alzheimer's Aβ Peptide: A Docking Study.
    Mirza Z; Beg MA
    Curr Alzheimer Res; 2017; 14(3):327-334. PubMed ID: 27842487
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The evolution of A beta peptide burden in the APP23 transgenic mice: implications for A beta deposition in Alzheimer disease.
    Kuo YM; Beach TG; Sue LI; Scott S; Layne KJ; Kokjohn TA; Kalback WM; Luehrs DC; Vishnivetskaya TA; Abramowski D; Sturchler-Pierrat C; Staufenbiel M; Weller RO; Roher AE
    Mol Med; 2001 Sep; 7(9):609-18. PubMed ID: 11778650
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RNA-sequencing reveals transcriptional up-regulation of Trem2 in response to bexarotene treatment.
    Lefterov I; Schug J; Mounier A; Nam KN; Fitz NF; Koldamova R
    Neurobiol Dis; 2015 Oct; 82():132-140. PubMed ID: 26071899
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biomimetic ApoE-Reconstituted High Density Lipoprotein Nanocarrier for Blood-Brain Barrier Penetration and Amyloid Beta-Targeting Drug Delivery.
    Song Q; Song H; Xu J; Huang J; Hu M; Gu X; Chen J; Zheng G; Chen H; Gao X
    Mol Pharm; 2016 Nov; 13(11):3976-3987. PubMed ID: 27700119
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human ApoE Isoforms Differentially Modulate Glucose and Amyloid Metabolic Pathways in Female Brain: Evidence of the Mechanism of Neuroprotection by ApoE2 and Implications for Alzheimer's Disease Prevention and Early Intervention.
    Keeney JT; Ibrahimi S; Zhao L
    J Alzheimers Dis; 2015; 48(2):411-24. PubMed ID: 26402005
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lack of support for bexarotene as a treatment for Alzheimer's disease.
    O'Hare E; Jeggo R; Kim EM; Barbour B; Walczak JS; Palmer P; Lyons T; Page D; Hanna D; Meara JR; Spanswick D; Guo JP; McGeer EG; McGeer PL; Hobson P
    Neuropharmacology; 2016 Jan; 100():124-30. PubMed ID: 26025659
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blocking the apolipoprotein E/amyloid-beta interaction as a potential therapeutic approach for Alzheimer's disease.
    Sadowski MJ; Pankiewicz J; Scholtzova H; Mehta PD; Prelli F; Quartermain D; Wisniewski T
    Proc Natl Acad Sci U S A; 2006 Dec; 103(49):18787-92. PubMed ID: 17116874
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of apoe/Abeta interactions in the pathogenesis of Alzheimer's disease and cerebral amyloid angiopathy.
    Holtzman DM
    J Mol Neurosci; 2001 Oct; 17(2):147-55. PubMed ID: 11816788
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.